West Lafayette, IN – Kylin Therapeutics, Inc announced today its newest member to the research and development team, Dr. Henry Li. Dr. Li brings more than 13 years experience of biopharmaceutical R&D, as well as additional years of academic research. Dr. Li began his career working at Immusol/iTherx Pharmaceuticals, a San Diego based biotechnology company, for over 11 years, holding various R/D positions, including management positions of Director of Oncology and Senior Director of Drug development. Dr. Li also has extensive experience in gene silencing related technologies, including RNAi and ribozyme based platforms. He created the first randomized ribozyme library for gene inactivation. After Immusol, Dr. Li was the Director of Research and Pharmacology at NexBio, a biopharmaceutical company focusing on novel biologic drug against pandemic influenza. At NexBio, Dr. Li was responsible for non-clinical development of Fludase, a clinical stage candidate, and other preclinical development.

Dr. Li was trained in molecular virology and cancer research, receiving Ph.D. from University of California, Irvine, and postdoctoral training at UCLA School of Medicine. He has been a productive researcher with expertise in cancer and infectious diseases. He has authored more than 50 publications that include both peer reviewed research and book chapters. He has also been awarded two SBIR grants as principal investigator. He has edited two drug development books and is currently on the editorial board of Journal Current Signal Transduction Therapy.

About Kylin Therapeutics Inc.
Kylin Therapeutics Inc. (http://www.kylintherapeutics.com) is a cutting-edge biotechnology company that employs a revolutionary RNA nanoparticle technology platform called “pRNA” to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies.